Beckman's thoughtful article (1) raises important questions regarding communication among hospitalists, patients, and primary care physicians. The field of hospital medicine continues to work on improving communication and transitions. As might be expected, some hospitalist programs communicate better than others-just like every other specialty and specialist.
TO THE EDITOR:
We appreciate and echo Beckman's appeal (1) for improved collaboration among hospitalists, primary care physicians, and administrators. His eloquent indictment of the discontinuity created by hospital medicine bears attention by all physicians.
Primary care is among the most difficult jobs in U.S. health care; the hospitalist model evolved in part to relieve that stress. However, as a result, medical care is a team endeavor now more than ever. The care improvements that this team delivers, however, are often hidden, whereas patients and their primary care physicians acutely feel the pain of discontinuity. This grief pervades Beckman's writing, but it should not: The efficiencies gained by primary care physicians, focused in their offices, allow them to touch and heal more patients than was previously possible. Older primary care physicians comment that their careers have been lengthened by hospitalists (Hovey D, Lipson J. Personal communication).
Communication lapses hurt all involved. Hospitalists study care transitions (2-4) and work to improve them. Last summer, Rochester General Hospitalist Group started tracking communication with primary care physicians by using an innovative computerized system. Tracking our data and providing individualized feedback led to a tripling of our communication frequency in the past 6 months; we now do this for 80% of patients who see primary care physicians with whom we are contracted.
Despite the "voltage drop" in information that occurs on care transitions in our institution, hospitalists (in partnership with our referring primary care physicians) have lower mortality rates, shorter lengths of stay, lower inpatient costs, and lower readmission rates than physicians who "do it all." Specialization brings benefits to patients, physicians, institutions, and payers.
Certainly, alprazolam and head computed tomography are harmful when inappropriately used. Without timely access to the ordering physician's notes and rationale, questioning their use is entirely appropriate. However, instead of seeking to protect "our" patient from our partnering physician on the other side of the hospital wall, we must create systems, such as electronic medical records, that give that partner prompt, useful (and thus reassuring) information.
Finally, the relationship between hospitalists and primary care physicians is complex. From one perspective, the hospitalist is seen as a service provider for the primary care physician, with the burden of communication on the hospitalist's shoulders. We argue that a professional relationship, requiring mutual responsibility, serves patients better. Perhaps soon, bundling payments (5) will generate shared reimbursement incentives, further encouraging collaboration. Hospitalists must respect the primacy of the patient's best-known provider and engage primary care physicians to improve care transitions. There is much exciting work to do, and we thank Beckman for emphasizing its importance.
As an academic general internist of similar vintage as Beckman (1), I sympathize with his sense of loss of the "old days," when the general internist was the utility player seeing patients in the office, following them through the emergency department and in and out of the intensive care unit, and discharging them back to the office. Admittedly, those days are gone, and no rearrangement of incentives is going to bring them back. Medicine and hospitals have gotten too complicated. However, a relatively simple incentive with a modest financial investment may help shore up a more patientcentered health care team. If office-based physicians were required to provide, could bill, and could be fairly reimbursed for a hospital visit on the day of admission and the day of discharge, incentives would be established to encourage "skilled explicit transitions of responsibility" to integrate the primary care physicians as integral members of the health care team and to instill in patients a sense of continuity care. The explicit point of the visit would be to close information gaps that occur as patients move from one point of the system to another. Although the immediate response to this suggestion would probably focus on yet another cost in an already cost-prohibitive health care system, we need only examine the costs of fragmented patient care relative to the benefits of eliminating potentially detrimental and demoralizing "degrees of separation." We can do better! 
Beckman's article (1) speaks brilliantly to concerns about hospitalist care, yet in so doing questions the very soul of modern medical practice. How do generalists see to the full spectrum of our patients' medical needs? What is lost as we partition inpatient from outpatient care? How has interphysician communication come to be regarded as an unexpected courtesy rather than an obligation? Why do so many physicians seem to regard one another as bungling adversaries rather than colleagues in a shared struggle?
The night before I read this article, I received an embarrassing e-mail. One of my patients-a 90-year-old woman with hypertension, diastolic heart failure, diet-controlled diabetes, and severe chronic low back pain-had been admitted to a local hospital after a fall. She was confused, hyperglycemic, volume-depleted, and in renal failure, all probably stemming from a urinary tract infection. Although she had been admitted to a hospitalist service and been seen by several physicians, no one had called to inform me of her hospitalization or to discuss her care. The embarrassing e-mail was from her son, asking why he hadn't heard from me and whether I was comfortable with his mother's treatment plan.
When I called the on-duty hospitalist, she was unfamiliar with the critical details of the case. She did not know my patient had had an infection and believed that the acute deterioration was due to a medication regimen with which she had been stable for years. She was unaware that my patient had heart failure and had glibly discontinued her therapy with an angiotensin-converting enzyme inhibitor, ␤-blocker, and diuretic, with no plan to reinstitute it. Finally, she was unapologetic about her team's lack of communication, arguing that the emergency department physician should have called me to discuss the admission and that she had been planning to contact me herself after she had discharged the patient. The conversation was chilling, and Beckman's observation that he had been regarded as "the local medical doctor from whom the patient needed to be protected" was fresh in my mind.
Beckman's assessment of hospitalist medicine is even-handed. He correctly argues that use of hospitalists may promote best practices, improve efficiency, and reduce medical errors, yet emphasizes that our current system is disjointed and isolating and leaves patients feeling abandoned. Yet, the truth toward which he nudges readers is that the difficulties of the hospitalist movement pervade our entire profession and are simply the outcroppings of a medical community in flux.
Hospitalists exist because general practitioners have tacitly agreed to cede ultimate responsibility for their patients to others. We don't cry foul when hospitalists or subspecialists neglect to communicate with us because we have accepted the premise that interphysician consultation is a burden rather than an opportunity to learn, build collegial relationships, and improve care for our patients. We are unsurprised when a hospitalist or consultant unilaterally changes a medical regimen because we have allowed our trainees to treat patients as if they live in a medical vacuum rather than a complex and often deep history of therapeutic failures and successes. Finally, in allowing the practice of medicine to become so subspecialized and compartmentalized, we have surrendered many of our diagnostic and therapeutic skills and much of our medical authority. Imagine regarding inpatient and outpatient medicine as virtually separate fields and believing that one cannot competently provide care in both venues! TO THE EDITOR: Beckman (1) details his experience with hospitalists managing his hospitalized inpatients. Hospitalist practice does fragment patient care in some ways. However, in this day and age, patients see multiple physicians in the outpatient setting, which also fragments the care process. A recent study (2) reported that Medicare beneficiaries saw a median of 2 primary care physicians and 5 specialists working in 4 different practices in 1 year. All of these physicians will probably order more tests and medications. The role of primary care internists has slowly been transformed into that of a care coordinator, rather than a mystical physician who miraculously diagnoses and cures unknown diseases. The advancement of technology, a plethora of specialists, and overuse of diagnostic tests have contributed to this. The emergence of hospitalist services is another facet of the same evolution. Contrary to Beckman's experience, several internists using hospitalist services report higher satisfaction, reduced interference of routine work, and a boost in revenue.
However, it is important to preserve the right of internists to see their own patients in the hospital if they so choose. Professional associations of internal medicine physicians have a role to play in accomplishing this. The hospitalist movement is still evolving and has problems, to which Beckman alludes. Another important point is that, similar to emergency medicine, hospitalist medicine has the potential to become a separate specialty. This might lead to further disintegration of internal medicine. Internal medicine physicians and leaders are responsible for working with hospitalists to keep them engaged rather than denouncing them for the shortcomings of the current system, which include such complex issues as communication and hand-offs. (1) find that Medicare spending is higher for previously uninsured persons and suggest that nearly half of the cost of expanding health insurance coverage to uninsured near-elderly adults might be offset by reduced spending in patients aged 65 years or older. We do not believe their research supports the notion of cost savings from insuring the uninsured, because a large proportion of higher Medicare expenditures observed for the previously uninsured cannot be avoided by insuring people earlier. As Bhattacharya points out (2), this may be particularly true if poor health caused them to be uninsured rather than lack of insurance causing them to have poor health.
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McWilliams and colleagues cannot adequately control for this reverse causation. The problem is exacerbated by their inclusion of persons from the Health and Retirement Study who acquired public insurance after 1992 but before age 65 years. Many adults who transition to public insurance before age 65 years probably had a health event that made them eligible for public insurance. This health event may have also caused them to be uninsured before obtaining public coverage. For example, persons who quality for Medicare before age 65 years because of participation in Social Security Disability Insurance (SSDI) qualify only after a 24-month waiting period after SSDI entitlement. Because they must be too disabled to work to qualify for SSDI, many are uninsured during the waiting period (3). According to our estimates based on the authors' sample definitions, 25% of the "uninsured" transitioned to public insurance before age 65 years, as opposed to only 11% of the "insured." Because disabled persons are more likely to use health care services and because their health characteristics are not adequately captured in the control variables, the authors' estimate includes spending that could not be avoided by insuring the uninsured. We calculate that the authors' estimate of the difference in Medicare spending between the uninsured and insured would decrease by 50% if persons who ever received public insurance before age 65 years were excluded from the sample.
Unrealistic expectations about the cost of health reform could lead to early dissatisfaction with reform efforts and result in curtailment. The costs of insuring near-elderly persons who are uninsured are unlikely to be offset by substantial reductions in Medicare spending in persons older than 65 years.
IN RESPONSE: Drs. Polsky and Decker reiterate 2 concerns raised in Bhattacharya's editorial (1) regarding our article: reverse causation and unmeasured confounding. We also had these concerns as we embarked on our research. However, after using rigorous statistical methods and carefully considering the relevant clinical evidence and empirical literature, we do not believe that they pose major threats to our main conclusion.
First, Drs. Polsky and Decker and Bhattacharya (1) note that poor health can cause people to lose their health insurance and that this causal sequence, rather than the reverse effects of lacking insurance on health, must explain our findings. To address this concern, we used a novel inverse-probability-of-treatment weighting approach to control for observed time-varying confounders, including declining health that may have led to loss of insurance. Thus, although chronic conditions may lead to denial or loss of coverage for some, our adjusted estimates more likely reflect the subsequent consequences of lack of insurance on chronic disease outcomes. Furthermore, research (2) suggests that health declines after loss of coverage occur much more frequently than the reverse in near-elderly adults.
Second, Drs. Polsky and Decker and Bhattacharya (1) argue that higher Medicare spending for previously uninsured adults was mostly explained by unobserved differences (for example, in disease control) before age 65 years that were not due to coverage differences and for which we did not adequately control. However, they offer no empirical evidence for this assertion. In contrast, a growing body of rigorous quasi-experimental research (3) (4) (5) (6) suggests that health insurance coverage substantially improves health outcomes, including disease control, for adults with conditions that can be treated effectively, such as cardiovascular disease and diabetes mellitus. This research has elucidated the clinical pathways by which covering the uninsured before age 65 years could lead to reductions in annual Medicare spending per beneficiary after age 65 years. Although we acknowledged that our observational analysis may have overestimated or underestimated these offsets to some extent, to assert that they are inconsequential is highly speculative and inconsistent with the demonstrated clinical benefits of Medicare coverage.
Drs. Polsky and Decker also question our inclusion of persons who were at first privately insured or uninsured but subsequently obtained public insurance before age 65 years because of disabilities. They assume that declining health in uninsured adults that led to eligibility for public coverage was unrelated to lack of insurance coverage and cite the higher rate of public coverage in our uninsured group as evidence of unmeasured confounding. However, this increased rate of transition to public insurance is also consistent with the cumulative adverse effects of lack of insurance on health. We addressed this potential source of bias by adjusting for observed timevarying measures of disability. Drs. Polsky and Decker suggest simply dropping persons with public coverage from the sample, but this approach would introduce another concerning source of bias by selectively excluding adults who may have been harmed most by lacking insurance. Nevertheless, even accepting their 50% reduction of our calculated cost offset to Medicare, the estimated offset from covering the current population of uninsured near-elderly adults would still be substantial: $49 billion. Although we agree with Drs. Polsky and Decker that the cost of expanding coverage should not be underestimated, the corresponding health and economic benefits should also be fully considered.
Should We Expand the Pharyngitis Paradigm for Adolescents and Young Adults?
TO THE EDITOR: Centor (1) presented an interesting article about management of pharyngitis in adolescents and young adults. The data on the Lemierre syndrome oblige us to be vigilant, but we disagree with the author's conclusions, especially as formulated in the second key summary point ("Use a penicillin or a cephalosporin for empirical treatment of rapid streptococcus-negative pharyngitis in adolescents and young adults"). Centor mentions that we do not have data on the clinical presentation of Fusobacterium necrophorum pharyngitis. Whether antibiotic therapy affects the duration and severity of pharyngitis symptoms or contagion is unknown, so these considerations cannot be included as a rationale for diagnosis and treatment. Nevertheless, without scientific evidence, Centor recommends treating the 30% of adolescents and young adults who present with at least 3 of the following symptoms: fever, tonsillar exudates, swollen tender anterior cervical adenopathy, or lack of cough. In this era of evidence-based-medicine, it is surprising that an author can recommend such management when no clinical trial has proven that it is effective or studied possible side effects, consequences for rate of resistance, and costs to the community and the patient.
To our pleasant surprise, we found an alternative recommendation at the end of the article. Students and residents must learn the natural history of routine pharyngitis: resolution in 3 to 5 days. This is a basic option in more and more guidelines in Europe (2) and even in North America. When disease does not resolve quickly, symptoms worsen, or unilateral neck swelling develops, physicians should consider an expanded differential diagnosis, including suppurative complications (peritonsillar abscess and the Lemierre syndrome). In those patients, physicians should obtain blood cultures and include clindamycin or penicillin-metronidazole. We agree with this management.
Until we have clinical trials on this topic, including the Lemierre syndrome, it does not seem necessary to invent a new paradigm-or to change the management of pharyngitis-even for adolescents and young adults.
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IN RESPONSE: Drs. De Meyere and Matthys presents a rationale for not changing the pharyngitis paradigm for adolescents and young adults. I disagree, but perhaps did not make my point clear enough.
Our current paradigm focuses solely on whether patients have group A ␤-hemolytic streptococcal pharyngitis. I am suggesting that we expand the paradigm to also include F. necrophorum pharyngitis.
What are the implications of a new paradigm? We who study pharyngitis have an obligation to learn more about F. necrophorum pharyngitis, to prevent the morbidity and mortality that can occur from that infection. Although we encourage early diagnosis of the Lemierre syndrome, we would rather prevent it. Only through a paradigm change will we collect the appropriate data to understand how to prevent the syndrome. Perhaps we will have better culture techniques, develop rapid tests, or identify the infection on the basis of clinical signs and symptoms. Regardless, expanding the paradigm will refocus our thinking about pharyngitis in adolescents and young adults. I believe that my article makes that case convincingly.
Matthys and colleagues' excellent review of pharyngitis guidelines (1) focuses on acute sore throat and does not mention the natural history or an approach to evaluating patients whose symptoms worsen. Adding such a recommendation is a paradigm expansion. We should both teach this concept and add this consideration to textbooks and guidelines.
In critiquing my recommendations, Drs. De Meyere and Matthys raise the controversy over empirical antibiotics for adolescent and adult pharyngitis. This controversy persists even though this practice has only a minor effect on unnecessary antibiotic use. I and coauthors addressed this issue in a perspective (2) in which we suggested that empirical treatment of patients with 3 or more of the 4 signs and symptoms would only result in 7.5% of adolescents and young adults without group A ␤-hemolytic streptococcus or group C ␤-hemolytic streptococcus pharyngitis receiving antibiotic treatment.
Linder and colleagues (3) have shown that inappropriate antibiotic use would decrease dramatically if physicians avoided giving antibiotics to patients with 2 or fewer of the predictive signs and symptoms. In a decision analysis (4), we found that the decision between treating empirically and treating only patients with positive rapid test results was a toss-up.
My main point was that physicians should not use macrolides for empirical treatment in this age group. Although I favor empirical therapy for these patients, I specifically acknowledge that some physicians will rationally choose not to use empirical therapy.
For more than 50 years, group A ␤-hemolytic streptococcus has been the focus of pharyngitis evaluation. Unless we consider F. necrophorum, we will not make progress in preventing the Lemierre syndrome or in diagnosing this potential fatal complication earlier.
CLINICAL OBSERVATION
Another Side to Statin-Related Side Effects
Background: Millions of persons take statins to reduce cardiovascular risk, and about 5% of those who take statins develop skeletal muscle symptoms and increased creatine kinase levels (1) . A variant in the gene SLCO1B1 increases susceptibility for this side effect by 5-fold (2). We reasoned that variants in other genes could occur in patients who were referred to us because of increased levels of creatine kinase and muscle pain or cramps.
Objective: To describe 3 patients in whom statin treatment unmasked an underlying muscle disorder.
Case Report: A 70-year-old salesman with no history of skeletal muscle disorders received simvastatin for hypercholesterolemia. He developed myalgia after long bicycle rides; however, he continued to take simvastatin for an additional 2 years. He was eventually evaluated for myalgia and a creatine kinase level of 250 U/L. The family history was unremarkable. We observed mild paresis on head flexion and arm abduction without myotonia. Eye examination and the rest of the physical examination were normal. Electrophysiologic studies showed no myotonic discharges or myopathic changes.
The creatine kinase level of a 65-year-old man with no previous reports of muscle disorders increased to 1700 U/L after treatment with atorvastatin and did not resolve when the patient switched to a different statin. When we asked, he reported exercise-induced myalgia that had not occurred before the statin therapy. No one in his family had muscle disease. He had mild proximal muscle weakness, and electromyographic results were normal. His records showed a creatine kinase level of 250 U/L before statin treatment.
A 56-year-old truck driver, who had performed hard manual labor all his life without muscle pain, started statin treatment because of hypercholesterolemia. Shortly thereafter, he developed muscle pain after heavy lifting or climbing more than 3 flights of stairs. His family history was negative for muscle disease. He had mild paresis of the head, arm, and hip musculature. His creatine kinase level was 750 U/L. Results of eye examination and the remaining physical examination were normal.
Methods and Findings: We performed muscle biopsy in 2 of the patients (Figure) and observed multiple central nuclei in the myocytes, variable fiber size, and increased connective tissue findings that are consistent with myotonic dystrophy type 2. We genotyped all 3 patients for the ZNF9 gene and focused on the known (CCTG)n expansion in intron 1. Each patient had the typical molecular defect underlying myotonic dystrophy type 2 (3). We did not find the SLCO1B1 variant that increases the risk for statin myopathy in either of the 2 patients (2).
Discussion: Nothing indicated that our 3 patients had an underlying chronic muscle disease until they began statin therapy. Muscular symptoms persisted after cessation of statin therapy. Therefore, we believe that statins unmasked myotonic dystrophy type 2 in our patients. Myotonic dystrophy type 2 is an autosomal-dominant disorder characterized by proximal muscle weakness, myotonia, and myalgia. Some patients have cardiac and metabolic abnormalities and cataracts. The gene variant in this disease causes aberrant RNA splicing and abnormal function of multiple target genes (4), which affect muscleblind-like proteins and myotubularin-related proteins. Other investigators (5) have associated genetic variants in myotubularinrelated protein 4 with plasma cholesterol levels, which may be a link between myotonic dystrophy type 2 and lipid metabolism and suggests that myotonic dystrophy type 2 caused the high cholesterol levels that led to the use of statins. Some investigators (3) have shown unprecedented somatic instability of the (CCTG)n expansion, with substantial increases of 2000 base pairs over 3 years. We do not know the mechanism of somatic instability or the time required for alteration of muscle histologic characteristics, but another possible explanation for our results is that statins caused CCTG expansion. Physicians should measure creatine kinase before prescribing statins.
